Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241657 | 0.89 | ALDH1A1 (0.64) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL2476165 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL5915613 | 0.81 | POLB (0.57) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL10251453 | 0.78 | ALDH1A1 (0.55) | ALDH1A1LMNAKMT2AMEN1HTT | |
| SCHEMBL7879510 | 0.77 | ALDH1A1 (0.54) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL505404 | 0.76 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2AMEN1HTT | |
| SCHEMBL15362318 | 0.75 | ALDH1A1 (0.68) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL20955891 | 0.75 | ALDH1A1 (0.60) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL15362323 | 0.74 | ALDH1A1 (1.00) | ALDH1A1LMNAKMT2ARAB9A | |
| SCHEMBL12686068 | 0.74 | ALDH1A1 (0.65) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414340-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | ALDH1A1 1708/4885LMNA 4054/4885L3MBTL1 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.